Icosapent ethyl

Icosapent ethyl has been studied in 34 papers since 2009: 7 trials and 2 observational studies in people, 22 reviews; 28 in the past year. It is an approved medicine. The newest paper, Nov 2, 2026: “AI-Derived Coronary CT Plaque Phenotyping as a Predictor of Response to Contemporary Cardiometabolic Pharmacotherapies: A Systematic Review and Meta-Analysis”.

InterventionApproved 2012

34 papers study it7 more mention it27 findingsUpdated

PubChemChEBI

9 new papers in 30 daysSee all 41 papers on icosapent ethyl

At a glance

A human trial reports better hospitalization-free survival with icosapent ethyl in statin-treated patients with cardiovascular disease or diabetes plus another risk factor. One group reports human results, including no clear cerebral blood-flow effect in cognitively unimpaired Veterans. Some trials across uses remain without posted results over a year after ending; companies fund papers, employ authors and sponsor trials.

27 findings in 21 papers from 2009 to 2026, 10 of them since August 2026

The findings reach people, from one lab or study. 8 independent labs in 8 countries; 21 trials, 2 about aging, 5 with no results posted.

“icosapent ethyl treatment was associated with fewer total hospitalizations (HR (95% CI) = 0.91 (0.84, 0.98), P=0.017)”
Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-ITEuropean journal of preventive cardiology2026doi:10.1093/eurjpc/zwag040

None of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 8 independent labs in 8 countries
  • 21 trials, 2 about aging, 5 with no results posted
  • Funders: Amarin Corporation and others
  • 4 of 15 findings with company ties
  • 8 of 21 trials sponsored by its developers
  • Human trial7
  • Humans2
  • In silico1

7 studies gave icosapent ethyl to people and measured what changed.

What changedDesignPeopleSource

down: Lowers the risk of cardiovascular disease29-30% risk reduction

Randomized trial6,921 peopleGood adherers (took study drug for ≥1.5 years)ESC Congress 2026 abstract, Oct 26, 2026

down: Decreases tissue factormedian 49.4 and 55.8 pg/mL, p=0.046

up: Improves event-free survivallog-rank p=0.022

Randomized trial2 years200 peopleIn high baseline TF patientsESC Congress 2026 abstract, Oct 26, 2026

down: Lowers the risk of hospitalizationHR 0.91, 95% CI 0.84-0.98, P=0.017

up: Improves survival without hospitalizationOR 1.12, 95% CI 1.02-1.22, p=0.016

down: Decreases days lost to hospitalization and deathRR 0.93, 95% CI 0.93-0.94, p<0.001

Randomized trialmedian 5.0 years8,179 people≥50 yearsMidlife adults; Older adults; statin-treated with established cardiovascular disease or diabetes and ≥1 additional risk factorEuropean journal of preventive cardiology, Jan 16, 2026

no change: Has no effect on pTau-217p-value range 0.10 - 0.98

Randomized trial18 months86 peopleMen50-76Midlife adults; Older adults; at risk for dementiaAAIC 2025 abstract, Dec 26, 2025

no change: Has no effect on cerebral blood flowMF p: 0.064-0.93; PI p: 0.061-0.94; CBF p: 0.33

Randomized trial18 months123 people50-75Midlife adults; Older adults; cognitively unimpaired VeteransAAIC 2025 abstract, Dec 25, 2025

What did studies of icosapent ethyl find?

18

Studies of icosapent ethyl measured 18 outcomes, among them mortality, serious adverse events and total atheroma volume.

Mortality

downin humans1

1 study
  1. Icosapent ethyl is linked with lower mortality in humans (FAERS disproportionality analysis, full study period 2012 onward) (ROR 0.495 (95% CI 0.427–0.574)).

    “For mortality, IPE showed a reduced overall signal (ROR 0.495, 95% CI: 0.427–0.574)”

    HumansFAERS disproportionality analysis, full study period 2012 onward

    Serious adverse events, hospitalization, and mortality associated with icosapent ethyl: a pharmacovigilance analysis using the FDA adverse event reporting system

    ESC Congress 2026 abstract

Serious adverse events

downin humans1

1 study
  1. Icosapent ethyl is linked with lower serious adverse events in humans (FAERS disproportionality analysis, full study period 2012 onward) (ROR 0.237 (95% CI 0.221–0.256)).

    “Icosapent ethyl showed consistently reduced serious adverse event signals across the full study period (ROR 0.237, 95% CI: 0.221–0.256)”

    HumansFAERS disproportionality analysis, full study period 2012 onward

    Serious adverse events, hospitalization, and mortality associated with icosapent ethyl: a pharmacovigilance analysis using the FDA adverse event reporting system

    ESC Congress 2026 abstract

Total atheroma volume

downin humans1

1 study
  1. Icosapent ethyl decreases total atheroma volume in humans (added to statin therapy, compared with statin-only therapy) (MD -77.50 (95% CI -302.47 to 147.47)).

    “Compared with statin-only therapy, the greatest reduction in TAV was observed with IPE (MD -77.50; 95% CI -302.47; 147.47)”

    Human trialadded to statin therapy, compared with statin-only therapycoronary arterymean follow-up 19 weeks

    Effects of residual risk–targeted therapies on coronary plaque regression: a network meta-analysis of 40 studies

    ESC Congress 2026 abstract

More on Total atheroma volume

Event-free survival

upin humans1

1 study
  1. Icosapent ethyl improves event-free survival in high baseline TF patients (log-rank p=0.022).

    “Patients with higher baseline TF demonstrated more favorable event-free survival under IPE treatment”

    Human trialin high baseline TF patients

    Effects of icosapent ethyl on coagulation biomarkers and their association with event-free survival in high-risk cardiovascular patients: a post hoc analysis of the REDUCE-IT

    ESC Congress 2026 abstract

Tissue factor

downin humans1

1 study
  1. Icosapent ethyl decreases tissue factor in humans (median 49.4 and 55.8 pg/mL, p=0.046).

    “TF blood levels were reduced after 2 years in IPE-treated patients compared with placebo (median 49.4 and 55.8 pg/mL, p=0.046).”

    Human trial2 yearsn = 200

    Effects of icosapent ethyl on coagulation biomarkers and their association with event-free survival in high-risk cardiovascular patients: a post hoc analysis of the REDUCE-IT

    ESC Congress 2026 abstract

More on Tissue factor

Cardiovascular outcomes

upin humans1

1 study
  1. Icosapent ethyl improves cardiovascular outcomes in humans (selected high-risk populations).

    “Icosapent ethyl and low-dose colchicine have demonstrated cardiovascular benefit in selected high-risk populations”

    Reviewselected high-risk populations

    Beyond LDL-C: Biomarker-Informed Risk Assessment and Management of Residual Cardiovascular Risk in the Era of Precision Prevention

    Diagnostics (Basel, Switzerland)

Cardiovascular events

downin reviews1

1 study
  1. Icosapent ethyl decreases cardiovascular events.

    “with icosapent ethyl showing meaningful cardiovascular benefit in the REDUCE-IT trial”

    Review

    Residual cardiovascular risk beyond LDL-cholesterol control: what remains unaddressed?

    American journal of cardiovascular disease

Cardiovascular risk

downin humans1

1 study
  1. Icosapent ethyl decreases cardiovascular risk in specific populations.

    “high-dose purified EPA (icosapent ethyl, 4 g/day) has demonstrated a substantial reduction in residual cardiovascular risk in specific populations.”

    Reviewin specific populations4 g/day

    Omega-3 Polyunsaturated Fatty Acid Formulations in Cardiovascular Prevention: Balancing Clinical Efficacy, Safety, and Environmental Sustainability

    Nutrients

Days lost to hospitalization and death

downin humans1RR 0.93

1 study
  1. Icosapent ethyl decreases days lost to hospitalization and death in humans among those who were hospitalized or died (RR 0.93, 95% CI 0.93-0.94, p<0.001).

    “fewer days lost among those who were hospitalized or died (RR (95% CI) = 0.93 (0.93, 0.94), p<0.001)”

    Human trialamong those who were hospitalized or died2 g twice dailymedian 5.0 yearsn = 8,179

    Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT

    European journal of preventive cardiology

Survival without hospitalization

upin humans1OR 1.12

1 study
  1. Icosapent ethyl improves survival without hospitalization in humans (OR 1.12, 95% CI 1.02-1.22, p=0.016).

    “Participants randomized to icosapent ethyl were more likely to survive until the end of the study without hospitalization (OR (95% CI) = 1.12 (1.02, 1.22), p=0.016)”

    Human trialstatin-treated with established cardiovascular disease or diabetes and ≥1 additional risk factor2 g twice dailymedian 5.0 yearsn = 8,179

    Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT

    European journal of preventive cardiology

pTau-217

no changein humans1

1 study
  1. Icosapent ethyl showed no clear effect on pTau-217 in humans (at risk for dementia) (p-value range 0.10 - 0.98).

    “Compared to placebo, 18 months of IPE therapy did not alter CSF biomarkers of vascular or metabolic health or a marker of AD pathology (pTau‐217)”

    Human trialat risk for dementiacerebrospinal fluid4g daily18 monthsn = 86

    Impact of icosapent ethyl on CSF NULISA vascular, metabolic, and AD biomarkers in cognitively unimpaired Veterans at risk for dementia

    AAIC 2025 abstract

More on pTau-217

Cerebral blood flow

no changein humans1

1 study
  1. Icosapent ethyl showed no clear effect on cerebral blood flow in humans (cognitively unimpaired Veterans) (MF p: 0.064-0.93; PI p: 0.061-0.94; CBF p: 0.33).

    “IPE treatment for 18 months did not significantly change MF, PI, or CBF measures (IPE: n = 41, placebo: n = 44; MF p ‐value range: 0.064‐0.93; PI p ‐value range: 0.061‐0.94; CBF p ‐value: 0.33).”

    Human trialcognitively unimpaired VeteransVascepabrain4 g daily18 months

    Effects of Icosapent Ethyl, APOE Genotype and CSF Biomarkers on 4D Flow MRI Metrics of Vascular Health in Cognitively Unimpaired Veterans

    AAIC 2025 abstract

More on Cerebral blood flow

Cerebral blood flow

no changein humans1

1 study
  1. Icosapent ethyl showed no clear effect on cerebral blood flow in humans (cognitively unimpaired Veterans) (MF p: 0.064-0.93; PI p: 0.061-0.94; CBF p: 0.33).

    “IPE treatment for 18 months did not significantly change MF, PI, or CBF measures (IPE: n = 41, placebo: n = 44; MF p ‐value range: 0.064‐0.93; PI p ‐value range: 0.061‐0.94; CBF p ‐value: 0.33).”

    Human trialcognitively unimpaired VeteransVascepa®4 g daily18 months

    Effects of Icosapent Ethyl, APOE Genotype and CSF Biomarkers on 4D Flow MRI Metrics of Vascular Health in Cognitively Unimpaired Veterans

    AAIC 2025 abstract

Menopause-Specific Quality of Life

no changein humans1

1 study
  1. Icosapent ethyl showed no clear effect on menopause-Specific Quality of Life in humans.

    “Menopause-Specific Quality of Life scores improved significantly over time in both groups but no significant differences were noted between them.”

    Human trialWomen with hot flashes and moderate to severe psychological distress; compared with placeboenriched ethyl-eicosapentaenoic acid8 weeksfemales

    Effects of ethyl-eicosapentaenoic acid omega-3 fatty acid supplementation on hot flashes and quality of life among middle-aged women: a double-blind, placebo-controlled, randomized clinical trial

    Menopause (New York, N.Y.)

Hot flash frequency

downin humans1

1 study
  1. Icosapent ethyl decreases hot flash frequency in humans (Mean decline of 1.58 hot flashes/day versus 0.50/day with placebo).

    “After 8 weeks, HF frequency and score decreased significantly in the E-EPA group compared with the placebo group.”

    Human trialWomen with hot flashes and moderate to severe psychological distress; compared with placeboenriched ethyl-eicosapentaenoic acid8 weeksfemales

    Effects of ethyl-eicosapentaenoic acid omega-3 fatty acid supplementation on hot flashes and quality of life among middle-aged women: a double-blind, placebo-controlled, randomized clinical trial

    Menopause (New York, N.Y.)

All 18

What is icosapent ethyl linked with?

8

Studies link icosapent ethyl with 8 measures, among them cardiovascular disease, cardiovascular events and atherosclerotic cardiovascular disease.

Cardiovascular disease

downin humans2

2 studies
  1. Icosapent ethyl lowers the risk of cardiovascular disease in humans (good adherers (took study drug for ≥1.5 years)) (29-30% risk reduction).

    “‘Good adherers’ were defined as participants who took IPE for ≥1.5 years (n=6921), and they experienced a risk reduction of 29-30%.”

    Human trialgood adherers (took study drug for ≥1.5 years)4g/dayn = 6,921

    Adherence and legacy effects of high dose eicosapentaenoic acid in hypertriglyceridemia and high CV risk – REDUCE-IT Legacy

    ESC Congress 2026 abstract

  2. Icosapent ethyl lowers the risk of cardiovascular disease in patients taking statins who have high triglyceride levels.

    “High-dose eicosapentaenoic acid shows substantial benefit in selected patients taking statins who have high triglyceride levels.”

    Reviewin patients taking statins who have high triglyceride levels2 g twice a day

    Indications for omega-3 fatty acid supplementation in prevention of cardiovascular disease: From fish to pharmaceuticals

    Canadian family physician Medecin de famille canadien

More on Cardiovascular disease

Cardiovascular events

downin humans1

1 study
  1. Icosapent ethyl lowers the risk of cardiovascular events in humans (selected patients with atherosclerotic cardiovascular disease).

    “Cardiovascular outcome data support icosapent ethyl, low-dose colchicine, dual-pathway antithrombotic therapy, and further ApoB lowering in selected patients.”

    Reviewselected patients with atherosclerotic cardiovascular disease

    Residual cardiovascular risk beyond LDL-C in ASCVD: Biological drivers, biomarkers, and therapeutic strategies

    Acta pharmaceutica Sinica. B

Atherosclerotic cardiovascular disease

downin reviews1

1 study
  1. Icosapent ethyl lowers the risk of atherosclerotic cardiovascular disease.

    “eicosapentaenoic acid ethyl ester (EPA-EE) as the evidence-based choice for atherosclerotic cardiovascular disease (ASCVD) risk reduction”

    Reviewethyl ester

    Natural Fish Oil Versus Purified Fish Oil: Composition, Efficacy, and Applications

    Journal of nutrition and metabolism

More on Atherosclerotic cardiovascular disease

Major ischemic events

downin humans1

1 study
  1. Icosapent ethyl lowers the risk of major ischemic events in humans (REDUCE-IT) (17.2% vs. 22.0%; hazard ratio 0.75).

    “In REDUCE-IT, icosapent ethyl 4 g/day reduced major ischemic events (17.2% vs. 22.0%; hazard ratio 0.75)”

    ReviewREDUCE-IT4 g/day

    Omega-3 Fatty Acids in the Management of Cardiovascular Disease Prevention

    Cardiovascular drugs and therapy

Atrial fibrillation

upin humans1

1 study
  1. Icosapent ethyl raises the risk of atrial fibrillation in humans (at pharmacological doses).

    “modest but consistent increase in atrial fibrillation risk at pharmacological doses”

    Reviewat pharmacological doses

    Omega-3 Polyunsaturated Fatty Acid Formulations in Cardiovascular Prevention: Balancing Clinical Efficacy, Safety, and Environmental Sustainability

    Nutrients

More on Atrial fibrillation

Major adverse cardiovascular events

downin humans1

1 study
  1. Icosapent ethyl lowers the risk of major adverse cardiovascular events in humans.

    “Icosapent ethyl (IPE), a highly purified ethyl ester of eicosapentaenoic acid (EPA), reduces major adverse cardiovascular events (MACE) beyond triglyceride lowering”

    Reviewhighly purified ethyl ester

    Targeting inflammation in cardiometabolic disease: Icosapent ethyl modulates monocyte-derived macrophages isolated from patients with cardiovascular disease with or without type 2 diabetes

    Diabetic medicine : a journal of the British Diabetic Association

Hospitalization

downin humans1HR 0.91

1 study
  1. Icosapent ethyl lowers the risk of hospitalization in humans (HR 0.91, 95% CI 0.84-0.98, P=0.017).

    “icosapent ethyl treatment was associated with fewer total hospitalizations (HR (95% CI) = 0.91 (0.84, 0.98), P=0.017)”

    Human trialstatin-treated with established cardiovascular disease or diabetes and ≥1 additional risk factor2 g twice dailymedian 5.0 yearsn = 8,179

    Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT

    European journal of preventive cardiology

Ischemic stroke

downin reviews1

1 study
  1. Icosapent ethyl lowers the risk of ischemic stroke.

    “For triglyceride lowering, recent randomized evidence supports icosapent ethyl for reducing IS risk.”

    Review

    Dyslipidemia management in stroke prevention: An individualized approach

    International journal of stroke : official journal of the International Stroke Society

More on Ischemic stroke

Has icosapent ethyl been tested in people?

2 of 21 about aging

Yes: 7 trials and 2 observational studies in people have been published, and 21 trials are registered.

Approved

  • FDA Vascepa

    Jul 26, 2012Angina, Unstable, Cardiovascular Diseases, Myocardial Infarction, Stroke, Severe Hypertriglyceridemia, established cardiovascular disease

  • EMA Vazkepa

    Mar 26, 2021Dyslipidemias

Repurposing

All 26

Stopped

  • NCT02940223TerminatedFatigue

    PI is requesting termination (closure) of this study.

Who is developing icosapent ethyl?

1 company: Mochida Pharmaceutical Company.

Companies
  • Mochida Pharmaceutical CompanyPhase 3hypertriglyceridemia

Trial sponsors

Funding

1 grant since 2018

US Department of Veterans Affairs

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    One group reports lower cardiovascular risk among adherent human trial participants; reviews describe cardiovascular benefits and increased atrial fibrillation risk at pharmacological doses. A human trial shows no clear effect on cerebrospinal-fluid pTau-217 in people at dementia risk. Two registered trials address aging; five trials for any use ended over a year ago without posted results; company ties include author affiliation and trial sponsorship.

  2. Summary rewritten as its findings changed.

    As it read before

    Icosapent ethyl lowers cardiovascular risk in adherent human trial participants, while reviews report increased atrial fibrillation risk at pharmacological doses. One group reports human results, including no clear cerebral-blood-flow effect in cognitively unimpaired Veterans. Two registered trials concern aging; five trials ended over a year ago without posted results, and company ties include a company-affiliated author and Amarin- and Mochida-sponsored trials.

  3. Summary rewritten as its findings changed.

    As it read before

    Human trials show no clear effect of icosapent ethyl on cerebral blood flow in cognitively unimpaired Veterans or pTau-217 in people at dementia risk. Reviews describe lower cardiovascular risk but increased atrial fibrillation risk at pharmacological doses. One registered trial concerns aging; five across indications ended over a year ago without posted results, and eight have Amarin or Mochida sponsorship.

  4. Summary rewritten as its findings changed.

    As it read before

    Reviews describe reduced cardiovascular risk with icosapent ethyl at 4 g/day in selected human populations, including fewer major ischemic events, but increased atrial fibrillation at pharmacological doses. Five of 22 registered trials ended over a year ago without posted results or citing papers; eight are sponsored by Amarin Pharma, Mochida Pharmaceutical Company or Zhejiang Doer Biologics.

  5. Summary written from the findings.

Latest

Dec 2025: 5Jan 2026: 4Feb 2026: 3Mar 2026: 2Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 2Sep 2026: 3Oct 2026: 8Nov 2026: 330 papers in 12 months

See all 41 papers on icosapent ethyl